Teva Pharmaceutical Industries Limited has successfully shifted its strategy, leveraging its generics business to fund growth in specialty medicines, driving a turnaround in performance. TEVA's "Pivot ...
It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ingredient in diabetes therapy Ozempic and obesity drug Wegovy, into the ...
Pacira BioSciences faces significant risk as generic challenges threaten Exparel, its flagship product responsible for 78% of 2024 revenue. PCRX's complex formulation, robust patent estate, and ...
After delivering one of its strongest quarters ever, pharmaceutical major Lupin Ltd. is preparing for the next leg of growth, anchored in complex generics, respiratory therapies, and targeted ...
A federal appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic version of its blockbuster heart failure drug Entresto. The US Court of Appeals for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback